ICE-Guided LAA Closure with a Conformable Foam Implant

Vivek Y. Reddy, MD^{1,2} & Petr Neuzil, MD, PhD¹

¹Homolka Hospital, Prague; ²Helmsley Electrophysiology Center, The Mount Sinai Hospital, New York

vivek.reddy@mountsinai.org



- Conflicts of Interest:
 - Grant support and/or Consultant: Abbott, Biosense-Webster & Boston Scientific
 - Study funded by Conformal Medical Inc.
- This presentation discusses FDA-<u>unapproved</u> devices.



Disclosures

• Consultant and/or Grant support:

Abbott, Ablacon*, Acutus Medical*, Affera*, Apama Medical*, Aquqheart*, Atacor*, Autonomix*, Axon*, Backbeat*, Biosense-Webster, Biosig*, Biotronik, Boston Scientific, Cardiofocus, Cardionomics, CardioNXT/AFTx, Circa Scientific*, Corvia Medical*, Dinova-Hangzhou Nuomao Medtech*, East End Medical*, EBR, EPD*, EPIX*, EpiEP*, Eximo*, Farapulse*, Fire1, Impulse Dynamics, Intershunt*, Javelin*, Kardium*, Keystone Heart*, LuxMed*, Manual Surgical Sciences*, Medlumics*, Medtronic, Middlepeak*, Newpace*, Nuvera*, Phillips, Pulse Biosciences, Sirona Medical*, Surecor*, Thermedical, Valcare*, Vizaramed*

* I have an equity stake in these companies

I will be discussing investigational devices without FDA or CE-Mark approval.



Conformal Prague Early Feasibility Study (EFS)


Conformal Medical's CLAAS implant

Single-arm, single-center ICE feasibility study

First-in-human, n=15

STUDY PROCEDURE FLOW:

- 1. Conscious sedation
- 2. ICE in RA
- 3. Trans-septal
- 4. ICE in LA
- 5. Fluoroscopy-/ICE-guided placement of the LAAC device
- 6. TEE confirmation
- 7. LAAC device release








Conformal LAAC Device

Conformal Foam Matrix Cup










Conformal LAAC Device


Designed to Attempt to Minimize Thrombus








Allows Seal Despite Off-Axis Positioning







Conformal CLAAS Procedure








Baseline Assessment

 77 y/o F Hx of falls (CHA₂DS₂-VASc 5)

■ TEE evaluation: 17 x 20 mm

Implant size: regular

Patient 1901-02







Placement & Recapture

Initial Placement (too deep)



Recapture




Patient 1901-02





Pre-Release Assessment

Tug Test WL: 127 WW: 255 [D] RAO: 24 CAU: 12 10/19/2019 11:36:46 AM Patient 1901-02







ICE Evaluation

Angio: Baseline



ICE Guided: Deployment



ICE Guided: Tug Test



Patient 1901-09



• 74 y/o F

Hx of epistaxis (CHA₂DS₂-VASc 4)

TEE evaluation: 24 x 27 mm


Implant size: regular



Angio: Position & Leak Assessment



ICE Guided: Leak Assessment



ICE Guided: Position Assessment



Patient 1901-09





Patient Demographics

Enrolled Patients	15
Successful implants	15 (100%)
Age	71.3 ± 10.8 yrs
Gender (Male/Female)	5 / 10 (67% / 33%)
CHA ₂ DS ₂ -VASc	4.1 ± 1.7
HAS-BLED	3.4 ± 1.4





Results

Device procedural complications	0
LAA diameters (mean / range)	11 – 28 mm
Conformal sizes used (n)	12 regular, 2 large
Placement time (min)	55.1 ± 20.6 min
Contrast (cc)	41.5 ± 14.5
FU (45D, 6M, 1Y) as of 23-Sept-2020	15, 15, 0
Leaks (45D)	1 @ 1 mm, 1 @ 2 mm
Device related thrombus (45D)	1





Conclusions

The Conformal LAAC device using an ICE / Conscious Sedation Protocol:

- Is feasible
- 2 sizes address a large range of LAA anatomies
- Ability to assess seal without TEE





Conformal Next Steps

ICE Protocol Additional 510 patients

- Evaluate Gen 2 Delivery System
- Validate pivotal device delivery protocol
- Complete in Q1 2021

Pivotal Trial (FDA IDE)

- RCT: Conformal LAAC vs Watchman-FLX
- 1:1, n ~ 1,400
- Primary endpoint: 1-year clinical events, seal
- Secondary endpoint: 18-month stroke & systemic embolism
- First patient: Q2 2021





Thank you



MOUNT SINAL SCHOOL OF MEDICINE



MOUNT SINAL SCHOOL OF MEDICINE